Patisiran for Transthyretin Cardiac Amyloidosis | NEJM

(2:5)

Onpattro (Patisiran) for Treatment of Polyneuropathy Caused by Hereditary ATTR Amyloidosis

(2:11)

HFA 23: APOLLO-B: Patisiran Treatment for Cardiac Amyloidosis

(3:12)

Update on Patisiran to Treat Hereditary ATTR

(1:57)

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

(17:37)

Patisiran for Pat!

(9:)

Dr.Gobind Rai Garg discusses the topic - Patisiran

(2:29)

Alnylam's Pending Approval of Patisiran

(1:7)

Optimism for amyloidosis therapy

(5:43)

Treating hATTR Amyloidosis: Historical Overview

(6:17)

3D Video Understanding ATTR Amyloidosis

(2:43)

Alnylam's New RNAi Therapy

(1:1econd)

New way to treat rare nerve disease

(2:2)

Patient living with hereditary ATTR Amyloidosis

(10:31)

Onpattro - meaning and Side effects

(3:2)

New Treatment for hATTR Amyloidosis

(9:43)

What is RNAi and Who is Investing in the Treatment?

(2:44)

Unboxing Patisiran/Onpattro for Hereditary Amyloidosis

(8:55)

RNAi Therapeutics - How this New Class of Medicines Works

(2:56)

Edward talks about his experience being on Onpattro at ThrIVewell Infusion.

(3:37)